News

• May 12, 2021

Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP

Read More >

• May 12, 2021

Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies

Read More >

• May 12, 2021

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

Read More >

• May 12, 2021

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

Read More >

• May 12, 2021

Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury

Read More >

• May 12, 2021

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

Read More >

• May 12, 2021

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

Read More >

• December 10, 2019

Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups

Read More >

• December 10, 2019

Quellis Biosciences Inc. Announces $17 Million Series A Financing

Read More >

• August 12, 2019

Landos Biopharma Completes $60 Million Series B Financing

Read More >